Tonix Pharmaceuticals Holding Corp., founded in 2007 and based in New York, spent the first ten years of its life developing lead compound, TNX-102, for the treatment of chronic pain condition fibromyalgia syndrome (FMS). But after a setback in Phase III for this indication earlier this year and positive results in another of its earlier stage clinical trials for the same drug in post-traumatic stress disorder, Tonix decided to shift gears and put all its resources into the latter condition.
Since committing to this change of direction in September this year, the company has won a breakthrough therapy designation from the US FDA on December 19, 2016 for the development of TNX-102 in PTSD – a condition currently considered an
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?